A5083298809- Multiple Myeloma Research and Treatments
- Peptidase Inhibition and Analysis
- Cancer Treatment and Pharmacology
- Protein Degradation and Inhibitors
- Advanced Proteomics Techniques and Applications
- Amyloidosis: Diagnosis, Treatment, Outcomes
- HIV/AIDS drug development and treatment
- PI3K/AKT/mTOR signaling in cancer
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Cancer, Hypoxia, and Metabolism
- vaccines and immunoinformatics approaches
- Insect Resistance and Genetics
- Inhalation and Respiratory Drug Delivery
- Polish Law and Legal System
- Acute Myeloid Leukemia Research
- Maritime Transport Emissions and Efficiency
- Chemotherapy-induced organ toxicity mitigation
- Environmental Policies and Emissions
- Malaria Research and Control
- Biochemical and Molecular Research
- Cancer therapeutics and mechanisms
- Ubiquitin and proteasome pathways
- Research on Leishmaniasis Studies
Poznan University of Medical Sciences
2015-2024
Authorised Association Consortium
2016
// Ravyn M. Thompson 1 , Dominik Dytfeld 2 Leticia Reyes Reeder Robinson Brittany Smith Yefim Manevich Andrzej Jakubowiak 3 Mieczyslaw Komarnicki Anna Przybylowicz-Chalecka Tomasz Szczepaniak Amit K. Mitra 5 Brian G. Van Ness Magdalena Luczak 4 Nathan Dolloff 1, * Department of Cell and Molecular Pharmacology & Experimental Therapeutics, Medical University South Carolina, Charleston, SC, USA Karol Marcinkowski Sciences, Poznan, Poland Chicago, IL, Institute Bioorganic Chemistry, Polish...
// Dominik Dytfeld 1, 9, * , Magdalena Luczak 2, 11, Tomasz Wrobel 3, Lidia Usnarska-Zubkiewicz 3 Katarzyna Brzezniakiewicz 9 Krzysztof Jamroziak 5, Giannopoulos 6, Anna Przybylowicz-Chalecka 1 Blazej Ratajczak Joanna Czerwinska-Rybak Adam Nowicki Monika Joks Elzbieta Czechowska 7, Zawartko 8 Szczepaniak Norbert Grzasko Marta Morawska Maciej Bochenek Tadeusz Kubicki Michalina 4, Tusznio 5 Andrzej Jakubowiak 10 Mieczysław Komarnicki Department of Hematology and Bone Marrow Transplantation,...
In the era of implementing novel agents in multiple myeloma (MM) regimens, drug resistance has become a key factor undermining results treatment. Identifying biomarkers allows prediction therapy outcomes with specific and may lead to avoidance resistance.This study aimed identify pretreatment sera patients refractory/ relapsed MM that differ from those who achieved better depth response bortezomib-containing therapy.Pretreatment serum samples were obtained 61 proteasome inhibitor-naive,...
Summary Previous studies suggest that postautologous stem cell transplant (ASCT) recovery of polyclonal immunoglobulin from immunoparesis in patients with multiple myeloma is a positive prognostic marker. We performed longitudinal analysis concentrations and unique B‐cell sequences enrolled the phase 3 ATLAS trial randomized 180 subjects to either carfilzomib, lenalidomide, dexamethasone (KRd) or lenalidomide (R) maintenance. In KRd arm, standard‐risk minimal residual disease negativity...
We present a case of 53-year-old male with symptomatic relapse IgGλ multiple myeloma who was readmitted to the hospital clinical symptoms retroperitoneal hematoma. Laboratory tests revealed high concentration monoclonal immunoglobulin G (32 g/l, 91.6% total IgG) in serum, prolongation activated partial thromboplastin time (aPTT), prothrombin (PT), and thrombin (TT), significantly decreased factor V procoagulant activity presence inhibitor. After successful retreatment use six cycles...
The article presents relations of distribution the low sulphur marine fuels as result being in force International Convention for Prevention Pollution from Ships (MARPOL) 73/78, especially record establishing region Baltic Sea and North See emission control areas (SECA). There are presented obligatory regulations their influence on sale particular kinds this region. also chosen procedures care about cargo relation bunker boat-harbour-ship, delivery fuel boat-ship quantitative analysis...
Background: Treatment following autologous stem cell transplantation (ASCT) for multiple myeloma (MM) remains an area of active investigation. We have shown that extended post-ASCT treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) after KRd induction improved the depth duration response (Jasielec et al, Blood 2020), suggesting a benefit therapy. Aims: report results ATLAS, multicenter, international, open-label randomized phase 3 study to determine efficacy safety KRD vs...